In addition, NAFLD impacts metabolism and CVD risk through hepatokines, such as fetuin-A, ANGPTL3 (angiopoietin-related protein 3), FGF21 (fibroblast growth factor 21), SHBG (sex hormone-binding globulin), selenoprotein P, fetuin-B and follistatin (42). Here, FST is linked to metabolic dysfunction-associated steatotic liver disease.